EN DE
Watch BRIM Biotechnology, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BRIM Biotechnology, Inc. (6885) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of BRIM Biotechnology, Inc. stock TWD 15.47, price TWD 26.85, that is 42.4% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

BB BRIM Biotechnology, Inc. logo Thin data Nov 10, 2026

BRIM Biotechnology, Inc.

6885 · TW
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Low debt
Mixed Growth (revenue 3y +118.5 %/yr in TWD)
Mixed vs. peers (4/7)
Fair value 15.47 TWD · Strongly overvalued
Quality 39/100
Negative free cash flow
Narrow moat 9/100
Thin data
Estimate
Watch BRIM Biotechnology, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

90.50 TWD 20.05 TWD Fair Value 15.47 TWD Jun 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

53‑month range 20.05 TWD – 90.50 TWD · fair‑value band 11.60 TWD – 19.34 TWD · the 26.85 TWD price screens above the 15.47 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow BRIM Biotechnology in your weekly email

Every Wednesday you see whether BRIM Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease.

Show moreShow less

It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis.

BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.

Stock analysis

BRIM Biotechnology, Inc. (6885) currently trades at 26.85 TWD, while our estimate is 15.47 TWD, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 11.60 TWD (bear) to 19.34 TWD (bull), the price of 26.85 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BRIM Biotechnology, Inc. reported revenue of 5.5M TWD in FY2025 versus 360K TWD in FY2021, a compound +97.6%/yr. Reported net income was −436M TWD in FY2025.

Key figures

Market cap 3.7B TWD (≈ $112M) Micro · EPS (TTM) −3.26 TWD · Return on equity −26.5% · Return on assets (EBIT) −24.0% (5-year average) · Operating margin −2,165% · Revenue (TTM) 10.6M TWD · Revenue growth (YoY) +152% · Free cash flow −654M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 20% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, 6885 screens richer than that median.

Fair Value

Bear 11.60 TWD Fair Value 15.47 TWD Bull 19.34 TWD
Price 26.85 TWD · Downside -42.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 59
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 35
Distance to the 52-week high, does not count
New shares 58
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,548.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+118.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−25,893.1% (2021) → −8,250.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6885 screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare BRIM Biotechnology, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −42.4% · Bottom 25%
Profitability
Return on assets −23.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 151.7% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.22× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 6885
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 6885
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 6885
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 6885
argenx SE ARGX $971.55 $908.40 −7% vs 6885
CSL Limited CSL A$201.68 A$181.40 −10% vs 6885
Moderna, Inc MRNA $250.83 $158.70 −37% vs 6885
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 6885
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 6885
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 6885

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BRIM Biotechnology, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BRIM Biotechnology, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6885

Frequently asked questions

Is BRIM Biotechnology, Inc. (6885) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 15.47 TWD versus a price of 26.85 TWD, about 42% lower (overvalued).
What is the fair value of 6885?
Our estimate for BRIM Biotechnology, Inc. is 15.47 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 26.85 TWD.
What is the quality score of 6885?
BRIM Biotechnology, Inc. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BRIM Biotechnology, Inc. (6885)?
Our calculated price target is the estimate of 15.47 TWD (as of Nov 10, 2026). Cautious scenario 11.60 TWD, optimistic scenario 19.34 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the BRIM Biotechnology, Inc. stock forecast for 2026?
Our estimate puts fair value at 15.47 TWD, about 42% lower versus a price of 26.85 TWD (overvalued). Cautious scenario 11.60 TWD, optimistic scenario 19.34 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of BRIM Biotechnology, Inc. (6885)?
BRIM Biotechnology, Inc. reported trailing-twelve-month revenue of about 10.6M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of BRIM Biotechnology, Inc. (6885)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BRIM Biotechnology, Inc. it is 15.47 TWD per share (as of Nov 10, 2026), against a price of 26.85 TWD.
Is BRIM Biotechnology, Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6885 trades above its calculated fair value: price 26.85 TWD, fair value 15.47 TWD, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6885?
No. The price is what the market pays today (26.85 TWD); the fair value is what the company's own numbers justify (15.47 TWD). For BRIM Biotechnology, Inc. the two are 11.38 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is BRIM Biotechnology, Inc. worth?
The market values BRIM Biotechnology, Inc. at about 3.7B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 26.85 TWD; our models calculate a fair value of 15.47 TWD per share.
What do the bullish and bearish scenarios say about 6885?
Our models span a range for BRIM Biotechnology, Inc.: cautious scenario 11.60 TWD, base 15.47 TWD, optimistic 19.34 TWD per share (as of Nov 10, 2026, price 26.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BRIM Biotechnology, Inc. (6885)?
Balance-sheet figures for BRIM Biotechnology, Inc. (as of Nov 10, 2026): return on equity −26.5%, debt of 0.00 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 6885 from its 52-week high?
BRIM Biotechnology, Inc. trades at 26.85 TWD, about 20% below its 52-week high of 33.60 TWD and 32% above the low of 20.30 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 15.47 TWD is for.
Which stocks are comparable to BRIM Biotechnology, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BRIM Biotechnology, Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price 26.85 TWD, calculated fair value 15.47 TWD (−42%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. BRIM Biotechnology, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BRIM Biotechnology, Inc. (6885)?
The closing price on Nov 10, 2026 was 26.85 TWD. Our estimate is 15.47 TWD, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BRIM Biotechnology, Inc. right now?
The price sits above even our optimistic bull case (19.34 TWD). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of BRIM Biotechnology, Inc.

How large is the market capitalisation of BRIM Biotechnology, Inc. (6885)?
The market capitalisation of BRIM Biotechnology, Inc. is 3.7B TWD (≈ $112M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of BRIM Biotechnology, Inc. (6885)?
Earnings per share at BRIM Biotechnology, Inc. are −3.26 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BRIM Biotechnology, Inc. (6885)?
The return on equity (ROE) of BRIM Biotechnology, Inc. is −26.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BRIM Biotechnology, Inc. (6885)?
On an EBIT basis the return on assets of BRIM Biotechnology, Inc. is −24.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BRIM Biotechnology, Inc. (6885)?
The operating margin of BRIM Biotechnology, Inc. is −2,165% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BRIM Biotechnology, Inc. (6885)?
Revenue at BRIM Biotechnology, Inc. is growing +152% versus a year earlier (3y avg +119%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BRIM Biotechnology, Inc. (6885) generate?
The free cash flow of BRIM Biotechnology, Inc. is −654M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch BRIM Biotechnology, Inc. in the live analysis

One click puts BRIM Biotechnology, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.